No Data
No Data
No Data
No Data
No Data
Allogene Therapeutics Announces Q2 Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
GlobeNewswireApr 9 08:30 ET
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Yahoo FinanceApr 7 10:22 ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
TipRanksMar 19 08:11 ET
Express News | HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
Moomoo 24/7Mar 19 06:55 ET
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 16 16:35 ET
Allogene Therapeutics' Stability Threatened by Banking Sector Turmoil
TipRanksMar 16 02:01 ET
Mafiosa818 : earnings tomorrow 8/2
103133239 Mafiosa818: will today be the day
Mafiosa818 103133239: looks green today
No Data
No Data